High-dose mizoribine treatment for adolescents with systemic lupus erythematosus

Pediatrics International

Volumn 48, Issue 2, 2006, Pages 152-157

  Nozu, Kandai ^a   Iijima, Kazumoto ^b   Kamioka, Ichiro ^a   Fujita, Teruo ^a   Yoshiya, Kunihiko ^c   Tanaka, Ryojiro ^d   Nakanishi, Koichi ^e   Yoshikawa, Norishige ^e   Matsuo, Masafumi ^a  

^a KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b NATIONAL CENTER FOR CHILD HEALTH AND DEVELOPMENT   (Japan)

^c Hara Genitourinary Hospital   (Japan)

^d Hyogo Children's Hospital   (Japan)

^e WAKAYAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

Adolescent; Hyperuricemia; Mizoribine; Systemic lupus erythematosus

Indexed keywords

COMPLEMENT COMPONENT C3; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DNA ANTIBODY; IMMUNOSUPPRESSIVE AGENT; METHYLPREDNISOLONE; MIZORIBINE; PREDNISOLONE;

ADOLESCENT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; FEMALE; HUMAN; HYPERURICEMIA; IMMUNOSUPPRESSIVE TREATMENT; MALE; PRIORITY JOURNAL; RECURRENT DISEASE; SCHOOL CHILD; STEROID THERAPY; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADOLESCENT; CHILD; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; RIBONUCLEOSIDES; URIC ACID;

EID: 33645392996     PISSN: 13288067     EISSN: 1442200X     Source Type: Journal    
DOI: 10.1111/j.1442-200X.2006.02178.x     Document Type: Article

References (22)

1. Yokota S. Mizoribine: mode of action and effects in clinical use. Pediatr. Int. 2002 44 196 8.
2. Yoshidome K Takei S Imanaka H Maeno N Ohkawa T Kawano Y. Efficacy of mizoribine in the treatment of systemic lupus erythematosus in children. Pediatr. Int. 2004 46 444 9.
3. Lacks S White P. Morbidity associated with childhood systemic lupus erythematosus. J. Rheumatol. 1990 17 941 5.
4. Aihara Y Miyamae T Ito S et al. Mizoribine as an effective combined maintenance therapy with prednisolone in child-onset systemic lupus erythematosus. Pediatr. Int. 2002 44 199 204.
5. Yokota S Shimizu H Aihara Y et al. Effect and limitation of intravenous methylprednisolone pulse therapy in the long-term follow-up of childhood systemic lupus erythematosus. Ryumachi 1992 32 215 22 (in Japanese with an English abstract).
6. Niaudet P. Treatment of lupus nephritis in children. Pediatr. Nephrol. 2000 14 158 66.
7. Boumpas DT Austin HA III. Vaughn EM et al. Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet 1992 340 741 5.
8. Manger K Kalden JR Manger B. Cyclosporin A in the treatment of systemic lupus erythematosus: results of an open clinical study. Br. J. Rheumatol. 1996 35 669 75.
9. Mok CC Lau CS Wong RW. Risk factors for ovarian failure in patients with systemic lupus erythematosus receiving cyclophosphamide therapy. Arthritis Rheum. 1998 41 831 7.
10. McDermott EM Powell RJ. Incidence of ovarian failure in systemic lupus erythematosus after treatment with pulse cyclophosphamide. Rheumatology 1998 41 831 7.
11. Iijima K Hamahira K Tanaka R et al. Risk factors for cyclosporine-induced tubulointerstitial lesions in children with minimal change nephrotic syndrome. Kidney Int. 2002 61 1801 5.
12. Amemiya H Suzuki S Niiya S Watanabe H Kotake T. Synergistic effect of cyclosporine and mizoribine on survival of dog renal allografts. Transplantation 1988 46 768 71.
13. Marumo F Okubo M Yokota K et al. A clinical study of renal transplant recipients receiving triple-drug therapy-cyclosporine A, mizoribine, and predonisolone. Transplant. Proc. 1988 20 406 9.
14. Sonda K Takahashi K Tanabe K et al. Clinical pharamacokinetic study of mizoribine in renal transplantation patients. Transplant. Proc. 1996 28 3543 8.
15. Yumura K Uchida N Kaeashima A et al. Evaluation of plasma concentration of mizoribine as an immunosuppressive agent in lupus nephritis patients. Jin to touseki 1999 47 705 8 (in Japanese).
16. Tanaka H Suzuki K Nakahata T Tsugawa K Ito E Waga S. Mizoribine oral pulse therapy for patients with disease flare of lupus nephritis. Clin. Nephrol. 2003 60 390 94.
17. Katayama T Uchida K Goto N et al. Evaluation of the blood mizoribine concentration during high-dose mizoribine administration (10 mg/kg/day) in the early period after kidney transplantation (Part 2). Ther. Res. 2003 24 986 8 (in Japanese).
18. Gulicklich D Acharya A. Mycophenolate mofetil therapy for lupus nephritis refractory to intravenous cyclophosphamide. Am. J. Kidney Dis. 1998 32 318 22.
19. Chan TM Li FK Tang CS et al. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. HongKong-Guangzhou Nephrol. Study Group. N. Engl. J. Med. 2000 343 1156 62.
20. Abe Y Seki M Nakada M et al. Pharmacokinetic study of mizoribine child onset renal disease. Jpn. J. Pediatr. Nephrol. 2004 17 29 33 (in Japanese).
21. Ueda N Imai Y. New action mechanism of bredinin. Nephrol. Front. 2003 2 69 75 (in Japanese).
22. Kushihata S Hirabayashi A Sekiguchi Y Nagai K Arata T. A case of acute renal failure with marked hyperuricemia developing during mizoribine administration. Jpn. J. Nephrol. 2002 44 543 6 (in Japanese with an English abstract).